Austrade invites Australian companies with capabilities across biotechnology, drug discovery & development and clinical trials to participate in our upcoming delegation to CPHI Japan in Tokyo from 21-23 April 2026. 

CPHI Japan is positioned as the bridge to Asia’s advanced pharma ecosystem. By joining CPHI Japan, you’ll gain access to Japan’s elite R&D track record, top suppliers across Asia and Japanese market insights.  

Austrade is coordinating a Team Australia pavilion for the first time at CPHI Japan to help Australian businesses diversify and capitalise on international growth opportunities.  

The Team Australia delegation to CPHI is part of Austrade’s newly launched Australian Clinical Trials Initiative (ACTI), which promotes Australia internationally as an attractive clinical trials destination. ACTI is a coordinated, national effort to promote the clinical trials sector through global trade missions and streamlined support. During the CPHI conference, we will host a private seminar to highlight Australia’s clinical trials ecosystem and world-leading capabilities. 

Participating Australian companies will receive full access to the CPHI Japan exhibition. This is only available to approved delegation participants – applications will be reviewed by our in-market specialists. 

CPHI Japan 2026 takes place in Tokyo just one week before our celebrated regional event, BioKorea. This is a great opportunity to leverage Austrade’s in-market expertise to explore and further establish Northeast Asian markets for your business.  

Why you should participate 

CPHI Japan is a key event for pharmaceutical businesses and trade professionals in Japan and the broader region. The exhibition attracts over 35,000 attendees and 800 exhibitors from 70 representing countries.   

It covers all sectors related to pharmaceutical ingredients, outsourcing, biopharma, pharma machinery and equipment, formulation and packaging.  

Australian clinical trials service providers, biotechnology companies and pharma manufacturers will have the opportunity to raise their profile on an international platform, unlock new export markets, increase export sales and build new partnerships and connections.    

We encourage companies across the following segments to apply: 

Austrade’s business program will include market briefings, tailored seminar presentations, on-site business meetings and networking during the event.   

250+ seminars held at CPHI Japan are a key attraction of this conference. The organiser carefully selects the theme to reflect the latest market trends and interests. Australian Clinical Trials has been selected as one of the highlight sessions, reflecting increased interest from drug developers in Japan.  

Who should participate?

Austrade invites expressions of interest from Australian health sector companies that are export ready and currently generating business revenue that meet the following criteria:

• registered Australian business with a current ABN 
• innovative capabilities and expertise in one of the following areas: 
  • Biotechnology
  • Drug development
  • Contract Manufacturing
  • Clinical trials sites and affiliated service providers
• a viable product offering, existing customers and revenue stream/s, or existing funding to support market expansion
• Australian health companies who have (or are looking to establish) a presence in the region and are interested in expanding to Japan
• ability to clearly describe and communicate company objectives and vision for growth
• ability to travel to Tokyo, Japan to attend all activities between 21-23 April 2026

If you are interested in participating, please register your interest by 6 March 2026. Austrade's country and sector specialists will review your application based on the above criteria and contact you regarding the outcome of your application. Please note there are limited slots available.

If successful, we will confirm your place in the program and provide further details on the program afterwards, including further advice on travel and accommodation logistics.